Related content

Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients

By Genazzani Alessandro D.   Prati Alessia   Santagni Susanna   Ricchieri Federica   Chierchia Elisa   Rattighieri Erica   Campedelli Annalisa   Simoncini Tommaso   Artini Paolo G.  

Gynecological Endocrinology, Vol. 28, Iss. 12, 2012-12 ,pp. : 969-973

Informa Healthcare

Access to resources Recommend Favorite

Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction

By Papaleo Enrico   Unfer Vittorio   Baillargeon Jean-Patrice   De Santis Lucia   Fusi Francesco   Brigante Claudio   Marelli Guido   Cino Ilaria   Redaelli Anna   Ferrari Augusto  

Gynecological Endocrinology, Vol. 23, Iss. 12, 2007-12 ,pp. : 700-703

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome

By Zacche Martino   Caputo Luigi   Filippis Susanna   Zacche Gabrio   Dindelli Moreno   Ferrari Augusto  

Gynecological Endocrinology, Vol. 25, Iss. 8, 2009-08 ,pp. : 508-513

Informa Healthcare

Access to resources Recommend Favorite

The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome

By Minozzi Massimo   Costantino Demetrio   Guaraldi Claudia   Unfer Vittorio  

Gynecological Endocrinology, Vol. 27, Iss. 11, 2011-11 ,pp. : 920-924

Informa Healthcare

Access to resources Recommend Favorite

Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia

By Genazzani Alessandro   Lanzoni Chiara   Ricchieri Federica   Baraldi Enrica   Casarosa Elena   Jasonni Valerio  

Gynecological Endocrinology, Vol. 23, Iss. 3, 2007-03 ,pp. : 146-152

Informa Healthcare

Access to resources Recommend Favorite